Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

The frequency of T regulatory cells modulates the survival of multiple myeloma patients: detailed characterisation of immune status in multiple myeloma

(2012) K Giannopoulos et al.   BRITISH JOURNAL OF CANCER

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

(2012) Yibin Yang et al.   CANCER CELL

The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma

(2012) Walter M. T. Braga et al.   Clinical & Developmental Immunology

Functional modulation of AMP-activated protein kinase by cereblon

(2011) Kwang Min Lee et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma

(2011) S. Madan et al.   BLOOD

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response

(2011) Antonia Lopez-Girona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients

(2011) T. Guglielmelli et al.   EUROPEAN JOURNAL OF CANCER

Pomalidomide therapy for multiple myeloma and myelofibrosis: an update

(2011) Martha Q. Lacy et al.   LEUKEMIA & LYMPHOMA

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism

(2009) L. Escoubet-Lozach et al.   CANCER RESEARCH

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

(2009) H Quach et al.   LEUKEMIA

Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation

(2009) C. Therapontos et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial

(2008) A. Palumbo et al.   BLOOD

Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

(2008) Dan Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

(2008) Christine Galustian et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

(2008) L. Wu et al.   CLINICAL CANCER RESEARCH

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

Dysregulation of large-conductance Ca2+-activated K+ channel expression in nonsyndromal mental retardation due to a cereblon p.R419X mutation

(2008) Joseph J. Higgins et al.   NEUROGENETICS